Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 19, 2021 - Issue 9
Submit an article Journal homepage
161
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Changes of recommended anticoagulation therapy in patients with atrial fibrillation and high thrombotic risk: long-term follow-up data from two hospital centers

Irzal Hadžibegovića Department for Cardiovascular Diseases, University Hospital Dubrava, Zagreb, Croatia;b Faculty of Dental Medicine and Health Care, Josip Juraj Strossmayer University, Osijek, Croatia;b Faculty of Dental Medicine and Health Care, Josip Juraj Strossmayer University, Osijek, CroatiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3768-9134View further author information
ORCID Icon,
Ivana Jurina Department for Cardiovascular Diseases, University Hospital Dubrava, Zagreb, Croatia;a Department for Cardiovascular Diseases, University Hospital Dubrava, Zagreb, CroatiaORCID Iconhttps://orcid.org/0000-0002-2637-9691View further author information
ORCID Icon,
Tomislav Letilovićc Department for Cardiology, University Hospital Merkur, Zagreb, Croatia;d Internal medicine department, Zagreb University School of Medicine, Zagreb, CroatiaORCID Iconhttps://orcid.org/0000-0003-1229-7983View further author information
ORCID Icon,
Vedran Radonićc Department for Cardiology, University Hospital Merkur, Zagreb, CroatiaView further author information
,
Hrvoje Jurind Internal medicine department, Zagreb University School of Medicine, Zagreb, Croatia;e Clinic for Cardiovascular Diseases, University Hospital Center Zagreb, Zagreb, CroatiaView further author information
,
Štefica Mikšićb Faculty of Dental Medicine and Health Care, Josip Juraj Strossmayer University, Osijek, CroatiaView further author information
&
Marko Lucijanićd Internal medicine department, Zagreb University School of Medicine, Zagreb, Croatia;f Department for Hematology, University Hospital Dubrava, Zagreb, CroatiaORCID Iconhttps://orcid.org/0000-0002-1372-2040View further author information
ORCID Icon show all
Pages 857-863 | Received 16 Mar 2021, Accepted 27 Jul 2021, Published online: 13 Aug 2021

References

  • Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2021;42:373-498.
  • Nührich JM, Kuck KH, Andresen D, et al. Oral anticoagulation is frequently discontinued after ablation of paroxysmal atrial fibrillation despite previous stroke: data from the German Ablation Registry. Clin Res Cardiol. 2015;104:463–477.
  • Hohnloser SH, Basic E, Nabauer M. Changes in oral anticoagulation therapy over one year in 51,000 atrial fibrillation patients at risk for stroke: a practice-derived study. Thromb Haemost. 2019;119:882–893.
  • Broderick JP, Bonomo JB, Kissela BM, et al. Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence. Stroke. 2011;42:2509–2514.
  • Olesen JB, Lip GYH, Hansen PR, et al. Bleeding risk in “real world” patients with atrial fibrillation: comparison of two established bleeding pre- diction schemes in a nationwide cohort. J Thromb Haemost. 2011;9:1460–1467.
  • Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
  • Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
  • Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
  • Shah RU, Rupp AB, Mowery D, et al. Changes in oral anticoagulant treatment rates in atrial fibrillation before and after the introduction of direct oral anticoagulants. Neuroepidemiology. 2016;47:201–209.
  • Loo SY, Dell’Aniello S, Huiart L, et al. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83:2096–2106.
  • Fawzy AM, Yang WY, Lip GYH. Safety of direct oral anticoagulants in real–world clinical practice: translating the trials to everyday clinical management. Expert Opin Drug Saf. 2019;18:187–209.
  • Beyer-Westendorf J, Förster K, Ebertz F, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015;17:530–538.
  • Jurin I, Lucijanić M, Šakić Z, et al. Patterns of anticoagulation in atrial fibrillation: results from a large real-life single-center registry. Croat Med J. 2020;61:440–449.
  • Lucijanic M, Jurin I, Jurin H, et al. Patients with higher body mass index treated with direct/novel oral anticoagulants (DOAC/NOAC) for atrial fibrillation experience worse clinical outcomes. Int J Card. 2020;301:90–95.
  • Li X, Pathadka S, Man KKC, et al. Comparative outcomes between direct oral anticoagulants, warfarin, and antiplatelet monotherapy among Chinese patients with atrial fibrillation: a population-based cohort study. Drug Saf. 2020;43:1023–1033.
  • Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–694.
  • Staerk L, Gislason GH, Lip GYH, et al. Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. Europace. 2015;17:1215–1222.
  • Feehan M, Walsh M, Van Duker H, et al. Prevalence and correlates of bleeding and emotional harms in a national US sample of patients with venous thromboembolism: a cross-sectional structural equation model. Thromb Res. 2018;172:181–187.
  • Erickson RM, Feehan M, Munger MA, et al. Understanding factors associated with quality of life in patients with venous thromboembolism. Thromb Haemost. 2019;119:1869–1876.
  • Sommerauer C, Schlender L, Krause M, et al. Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults - a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing. BMC Geriatr. 2017;17:223.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.